Hypofraktion strålebehandling for lokalt avanceret ikke-småcellet lungekræft
Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Trial title: Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non-small cell lung cancer: A phase II clinical trial.
Trial objective: To explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.
Trial Design: To enroll 36 patients diagnosed with stage III locally advanced non-small cell lung cancer to receive hypofraction radiotherapy (18 patients receiving high dose of 60 (Gray, Gy) /15 (fraction, f) and 18 patients receiving low dose of 48Gy/12f) followed by 1-year maintenance of immune checkpoint inhibitors.
Inclusion Criteria: a. 18-70 years old; b. Eastern Cooperative Oncology Group (ECOG) 0-1; c. non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma; d. wild-type of driven genes; e. stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and Positron Emission Tomography (PET-CT); f. surgically unresectable or deny of surgery; g. signature of inform consent.
Exclusion Criteria: a. younger than 18 years old or older than 70 years old; b. ECOG>1; c. small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma; d. mutant type of driven genes; e. Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT; f. surgically resectable; g. no signature of inform consent.
Staging Examination before Radiotherapy: a. ECOG scoring. b. Cranial contrast MRI and PET-CT, or cranial contrast MRI (preferred), chest contrast CT, abdominal ultrasonography and bone scan. c. Bronchoscopy for centrally-located lung cancer. d. Staging examination is mandatory after inductive chemotherapy & chemotherapy with immunotherapy. e. Pulmonary function test.
Inductive therapy before radiotherapy: Chemotherapy or chemotherapy combined with immunotherapy is allowed as inductive therapy. Detailed regimen could refer to NCCN guidelines. Tyrosine kinase inhibitors are not allowed as inductive therapy.
Randomization: Patients would be randomly assigned to high dose group and low dose group using random number table method.
Radiotherapy CT simulation: 4-Dimensional CT (4D-CT) with intravenous contrast is recommended for simulation. Scan thickness should be less than 5 mm. Thermal mask or vacuum bag is recommended.
Target Delineation: Considering hypofraction and involved field irradiation (IFI), only Internal Tumor Volume (ITV) should be delineated without the need to delineate Clinical Tumor Volume (CTV).
Delineation of ITV: ITV should include pulmonary gross tumor and metastatic mediastinal lymph nodes. PET-CT registration with simulation CT is recommended for patients with obstructive atelectasis. For patients with suspected mediastinal lymph nodes, Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is recommended.
Production of Planning Tumor Volume (PTV):
Low-dose Arm (48Gy/12f) PTV: PTV is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.
High-dose Arm (60Gy/15f) PTV: Planning Tumor Volume (PTV) is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.
The protection of OAR was given higher priority than the prescription dose coverage of PTV. The dose to PTV in adjacent to or abutting esophagus and spinal cord could be compromised with the lowest coverage rate of 90%.
Dosimetric Limitation:
Total Lung: V20<23%, Dmean<13Gy, V5<50%. Spinal Cord: Dmax<40Gy. Heart:V42<15cc, Dmax<48.9Gy in high-dose arm, V36.6<15cc, Dmax<42.5Gy in low-dose arm.
Great Vessels: V57<10cc,Dmax<65Gy in high-dose arm, V55.7<10cc,Dmax<62.9Gy in low-dose arm.
Esophagus: V45<2.5cc in high-dose arm, V40<2.5 cc in low-dose arm. Proximal Bronchial Tree: V55.5<5cc, Dmax<65Gy in high-dose arm, V52<5cc, Dmax<59Gy in low-dose arm.
Branchial Plexus: V48<3cc, Dmax<52.5Gy in high-dose arm, V37<3cc, Dmax<43Gy in low-dose arm.
Treatment Implementation: Radiotherapy is implemented every day. Cone-beam CT should utilized every day to minimize set-up error.
Concurrent Chemotherapy:For patients who have received over 4 cycles of inductive chemotherapy with or without immunotherapy, no concurrent chemotherapy is needed. For patients who had not received induction therapy or less than 4 cycles of inductive chemotherapy with or without immunotherapy, concurrent chemotherapy is needed to ensure 4 cycles of chemotherapy. Adenocarcinoma: Pemetrexed combined with platinum is recommended. Squamous-cell lung cancer: Etoposide combined with platinum is recommended. One month after completion of radiotherapy, chest CT and abdominal ultrasonography should be undertaken. After exclusion of disease progression and grade 2 or more radiation-induced pneumonitis, consolidative immunotherapy should be started. Durvalumab maintenance for one year is recommended.
Follow-up: Patients should be follow-up every three months right after the completion of radiotherapy to 3 years after radiotherapy. Then follow-up every half year is allowed to 5 years after radiotherapy. After 5 years, follow-up every year is appropriate. In follow-up, chest CT and abdominal ultrasonography should be implemented. Cranial MRI should be performed every half year for patients with adenocarcinoma. Bone scan should be undertaken every year for all patients.
Primary Endpoint: Rate of radiation-induced pneumonitis, esophagitis, central hilar structure injury rate, hematologic toxicity (CTCAE V4.0).
Secondary Endpoint: Median overall survival, 2-year overall survival rate, Median progression-free survival, 2-year progression-free survival, Objective response rate, Complete response rate, Partial response rate (RECIST v1.1).
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Anhui
-
Hefei, Anhui, Kina
- Anhui Provicial Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18-70 years old;
- Eastern Cooperative Oncology Group (ECOG) 0-1;
- Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma;
- Wild-type of driven genes;
- Stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT);
- Surgically unresectable or deny of surgery;
- Signature of inform consent.
Exclusion Criteria:
- Younger than 18 years old or older than 70 years old;
- ECOG>1;
- Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
- Mutant type of driven genes;
- Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
- Surgically resectable;
- No signature of inform consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: High-dose Arm
Irradiation of 60Gy/15f is administered followed by one-year immunotherapy maintenance. |
Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f with one-year immunotherapy maintenance. |
|
Eksperimentel: Low-dose Arm
Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance. |
Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/12f with one-year immunotherapy maintenance. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of radiation-induced pneumonitis (CTCAE V4.0)
Tidsramme: 1 to 2 years
|
Rate of radiation-induced pneumonitis (CTCAE V4.0) |
1 to 2 years
|
|
Rate of radiation-induced esophagitis (CTCAE V4.0)
Tidsramme: 1 to 2 years
|
Rate of radiation-induced esophagitis (CTCAE V4.0) |
1 to 2 years
|
|
Rate of central hilar structure injury (CTCAE V4.0)
Tidsramme: 1 to 2 years
|
Rate of central hilar structure injury (CTCAE V4.0) |
1 to 2 years
|
|
Rate of hematologic toxicity
Tidsramme: 1 to 2 years
|
Rate of hematologic toxicity |
1 to 2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Median overall survival (RECIST 1.1)
Tidsramme: 1-2 year
|
Median overall survival (RECIST 1.1) |
1-2 year
|
|
2-year overall survival rate (RECIST 1.1)
Tidsramme: 2 year
|
2-year overall survival rate (RECIST 1.1) |
2 year
|
|
Median progression-free survival (RECIST 1.1)
Tidsramme: 1-2 year
|
Median progression-free survival (RECIST 1.1) |
1-2 year
|
|
2-year progression-free survival rate (RECIST 1.1)
Tidsramme: 2 year
|
2-year progression-free survival rate (RECIST 1.1) |
2 year
|
|
Objective response rate
Tidsramme: 3 months after radiotherapy
|
Objective response rate |
3 months after radiotherapy
|
|
Complete response rate
Tidsramme: 3 months after radiotherapy
|
Complete response rate |
3 months after radiotherapy
|
|
Partial response rate
Tidsramme: 3 months after radiotherapy
|
Partial response rate |
3 months after radiotherapy
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ky270
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .